In prostate carcinoma, overexpression of the anti-apoptotic gene 
Introduction
Bax is a pro-apoptotic member of the Bcl-2 family of genes that regulate apoptosis. 1 Aberrations in the apoptotic pathway have been implicated in the progression of malignancy. 2 It has been determined that both chemotherapy and radiation cause death of tumor cells through the induction of apoptosis. 3 There is, likewise, evidence that dysregulation of apoptosis occurs in malignant cells that are resistant to therapy. 4 The resistance of tumor cells to therapy is probably mediated by mutations in genes involved in apoptosis. For example, p53 tumor suppressor gene mutations occur frequently in many forms of cancer. It has been found that p53 regulates the expression of Bax and Bcl-2. gene expression as well as repressing Bcl-2 transcription; therefore, mutations rendering p53 nonfunctional may lead to overexpression of Bcl-2 which could alter the ratio of pro-apoptotic to anti-apoptotic genes and lead to the protection of tumor cells from apoptotic-inducing signals. 6 Mutations in Bax gene are associated with ovarian, 7 colon, 8 and endometrial cancers, 9 and due to this observation, Bax is thought to have tumor suppressor activity. Overexpression of Bcl-2 in prostate cancer is associated with progression to an androgen-independent phenotype, which is resistant to therapies including radiation and androgen ablation. 10 Androgen-independent prostate cancer is the end-stage, lethal form of the disease currently without effective treatments. Thus, novel treatment strategies need to be developed.
Because restoring the balance of Bcl-2 family members would probably result in induction of apoptosis in prostate cancer cells, a logical strategy for gene therapy of prostate was to overexpress Bax. Bax is a 21 kDa protein that binds other members of the Bcl-2 family through its BH3 (Bcl-2 homology region 3) domain and functionally antagonizes its anti-apoptotic activity. The ratio of proapoptotic to anti-apoptotic proteins is thought to be the determining factor as to whether the cell will undergo apoptosis. Bax associates with the mitochondrial permeability transition pore complex (PTPC) to induce the release of cytochrome c, which interacts with apoptosis activating factor 1 (Apaf-1) and leads to activation of the caspase cascade through pro-caspase 9 cleavage resulting in apoptosis. 11 Overexpression of Bax through adenoviral gene transfer has been shown to induce apoptosis in ovarian, 12 breast, 13 lung, 14, 15 gastric, 16 and skin cancer. 17 Construction of first-generation adenovirus vectors with constitutively active promoters that express a cytotoxic gene is difficult due to toxicity of the transgene in the packaging cell line. Strategies have been developed to grow cytotoxic adenoviral vectors in modified packaging cells. For instance, adenovirus expressing Fas ligand is grown in 293 cells stably transfected with a poxvirus protein, crm A, which suppresses the caspase cascade. 18 This method, however, is only effective for genes whose function is inhibited by crm A. The development of 293 packaging cells overexpressing Bcl-2 did not abrogate Bax-induced apoptosis. Some studies utilized a dual-vector Bax adenovirus system. Others used an inducible promoter to achieve high levels of Bax expression, but this approach reduces the efficiency of vector delivery and increases the cost of treatment.
14 A single-vector system can be utilized through the use of a tissue-specific promoter, which has a considerable additional advantage for gene therapy purposes as well. 19 With the use of cytotoxic genes such as Bax, restriction of expression to target cells is clearly desirable. Previous testing of prostate-specific promoters revealed that the ARR 2 PB promoter has a very high level of prostate-specific expression. 20 A problem with retaining tissue specificity of promoters in adenoviral vectors exists in first-generation adenoviral constructs with insertion into the E1-deletion site proximal to the E1 enhancer. 20 The deletion of the E1 enhancer sequence is not practical because it overlaps with the adenoviral packaging sequence which mediates the packaging of the viral genome into capsids. We, and others, have found considerable background promoter activity with the use of the insertion site immediately downstream of the left inverted terminal repeat (ITR) and the E1 enhancer/packaging signal. [20] [21] [22] Our results demonstrated a significant increase in nonspecific ARR 2 PB activity when placed in the E1 insertion site as compared with insertion into a site near the right ITR. We confirmed the existance of an enhancer effect resulting from cis-acting elements located near the left ITR causing alteration of tissue specificity and activity of the promoter. 20 For this reason, we constructed a second-generation adenoviral vector with the prostate-specific ARR 2 PB promoter directing expression of an HA-tagged Bax gene and a green fluorescent protein reporter translated from an internal ribosome entry site into an insertion site near the right ITR (ARR 2 PB.Bax.GFP).
The ARR 2 PB promoter contains two androgen-responsive regions (ARR) with androgen receptor (AR)-binding sites; ARBS-1 at −236 to −223 bp and ARBS-2 at −140 to −117 bp. The ARR 2 PB promoter is strongly induced by androgens as well as glucocorticoids due to the androgen response elements also containing a minimal glucocorticoid response element (GRE) contained within the ARR. 23 Glucocorticoid induction of ARR 2 PB raises questions of whether the promoter will retain tissue specificity in vivo, however, evaluation of promoter activity in transgenic mice revealed stringent prostate-specific transgene expression. 23 We 
Results

Generation of an adenoviral vector expressing Bax with a prostate-specific promoter
Overexpression of the pro-apoptotic gene, Bax, is known to be toxic to many cell lines including the 293 packaging cell line utilized for propagation of adenoviral vectors. 12 This observation precluded the construction of a firstgeneration, E1-deleted CMV-driven Bax adenoviral vector. After numerous attempts to construct a CMV-Bax adenoviral vector failed, even in Bcl-2 expressing 293 cells, we chose to construct a second-generation, prostatespecific Bax adenoviral vector, Ad/ARR 2 PB.Bax.GFP. This approach prevented expression of Bax in the 293/Bcl-2 cells allowing propagation of the virus. This construct also allowed us to use a single-vector delivery system, rather than using a two-vector system as has been described previously. 14 The green fluorescent reporter gene was inserted after an internal ribosome entry site (IRES) to allow for ease of detection following infection with Ad/ARR 2 PB.Bax.GFP. 24 In order to prevent interference of the E1 enhancer with prostate specificity of the promoter, the transgene cassette was inserted into a site near the right ITR of the adenoviral vector. (Figure 1 ). The adenoviral vectors used in this study were generated in vitro and subsequently transfected into 293/Bcl-2 cells for propagation of adenovirus. 18 Time-course analysis of Bax expression following Ad/ARR 2 PB.Bax.GFP infection To confirm expression of Bax protein in cultured prostate cancer cells by adenovirus-mediated gene transfer, LNCaP cells were infected at a multiplicity of infection (MOI) of 100 (p.f.u. per cell) with either Ad/ARR 2 PB.Bax.GFP or Ad/CMV.GFP or mock-infected, and 10 nm dihydrotestosterone (DHT) was added for induction of the promoter. Cells were harvested at 6, 12, 24 and 48 h after infection and lysates were subjected to Western blot analysis. The HA-tagged Bax protein was detected at 24 h after infection with high levels of HA-Bax detected at 48 h ( Figure 2 ).
Visualization of morphological changes in cells following infection with Ad/ARR 2 PB.Bax.GFP
To examine the effect of Bax expression in prostate cancer cells, LNCaP cells were infected with either Ad/ARR 2 PB. Bax.GFP or a control Ad/CMV.GFP and evaluated by fluorescent microscopy ( Figure 3) . Cells infected at a MOI of 250, with the addition of 10 nm DHT, at 48 h after infection were observed for changes in morphology and cytopathology. Over 80% of the cells treated with Ad/ARR 2 PB.Bax.GFP showed signs of cytotoxicity, and became rounded and detached. In contrast, cells infected at the same MOI with Ad/CMV.GFP control virus did not show signs of cytotoxicity and remained in monolayers with normal morphology. This suggests that over Gene Therapy expression of the Bax transgene in these cells results in significant apoptosis.
GFP adenoviral vector. Schematic of second-generation (E1, E3, E4)-deleted, replication-incompetent adenovirus. ARR 2 PB is a modified probasin promoter driving expression of the Bax gene and green fluorescent protein reporter through the use of an internal ribosome entry site (IRES). BGH is bovine growth hormone poly
Tissue-specific expression of Ad/ARR 2 PB.Bax.GFP in human cancer cell lines
To examine the prostate-specific expression of Bax in cultured mammalian cell lines, a panel of human prostate (LNCaP, LNCaP/Bcl-2, CWR22RV1) and non-prostate cell lines (A549, HeLa, SK-Hep-1) were infected with Ad/ARR 2 PB.Bax.GFP at a MOI of 100, and 10 nm DHT was added. Forty-eight hours after infection, cell lysates were subjected to Western blot for HA-Bax as well as endogenous Bax and Bcl-2 expression and compared with lysates of uninfected cells. Infectivity of all cell lines was determined by infection with Ad/CMV.GFP and analyzed by flow cytometry using GFP expression as the reporter (data not shown). Only LNCaP and LNCaP/Bcl-2 cells (which have been stably transfected to overexpress Bcl-2) showed expression of the HA-Bax protein in cell lysates (Figure 4) . Endogenous Bax and Bcl-2 levels were unchanged in all cell lines tested. Thus, we have demonstrated that Bax expression is limited to prostate cancer cells that activate the ARR 2 PB probasin promoter in the context of infection with Ad/ARR 2 PB.Bax.GFP.
Cytotoxicity of Ad/ARR 2 PB.Bax.GFP in human cancer cell lines
To test whether expression of Bax by adenovirusmediated gene delivery would induce cytotoxicity in cultured human cancer cell lines, human prostate and nonprostate cells were infected with Ad/ARR 2 PB.Bax.GFP or Ad/CMV.GFP or mock-infected at increasing MOIs of 0.5, 5, 10, 50, 250 and 500, with the addition of 10 nm DHT. Cells were collected 48 h after infection, stained with a cell viability dye, 7AAD, and analyzed by flow cytometry for GFP expression and cell viability. Evidence of cytotoxicity was seen only in LNCaP and LNCaP/Bcl-2 cells with cytotoxicities of 85% and 82%, respectively ( Figure 5 ). All other cells showed modest decreases in cell viability equivalent to that seen with Ad/CMV.GFP control virus. PC3, PPC-1, and Du145 cells were also tested by infection with Ad/ARR 2 PB.Bax.GFP, but no Bax expression from ARR 2 PB was detected due to a lack of functioning androgen receptor (data not shown). This again demonstrates specificity of Bax-induced cell death via infection with Ad/ARR 2 PB.Bax.GFP in AR+ cells.
Figure 4 ARR 2 PB activity is restricted to LNCaP human prostate cancer cells. (a) Endogenous levels of Bax and Bcl-2 in a panel of human cancer cell lines. (b) Panel of human cancer cell lines infected with
Time-course analysis of caspase 3 activation
To determine whether apoptosis was induced in prostate cancer cells after infection with Ad/ARR 2 PB.Bax.GFP, activation of caspase 3 was examined. The timing of apoptotic events was determined by a time-course infection of LNCaP cells with MOI 250 of either Ad/ARR 2 PB.Bax.GFP, Ad/CMV.GFP or mock-infected at time-points of 12, 18, 24, 36 and 48 h before FACS analysis. At time-point 0, cells were lifted, permeabilized, and stained with anti-active caspase 3 mAb and analyzed by flow cytometry. Cells infected with Ad/ARR 2 PB. Bax.GFP showed no caspase 3 activity at time-points of 12, 18, and 24 h after infection (Figure 6c, d, e) . However, caspase 3 activation was observed starting at 36 h after infection (17%) (Figure 6f ) and extensive caspase 3 activation at 48 h after infection (32%). (Figure 6g ) In contrast, cells infected at the same MOI with Ad/CMV.GFP (Figure 6b ) and mock-infected cells (Figure 6a ) showed no evidence of caspase 3 activity. These results suggest that Bax expression by this system activated the caspase cascade resulting in apoptosis in the LNCaP human prostate cancer cell line.
Confirmation of apoptosis by TUNEL method
To assess further whether cell death, induced by Bax overexpression in LNCaP cells and LNCaP/Bcl-2, was via apoptosis, cells were analyzed by TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling). Cells, infected at a MOI of 250 for 24 and 48 h, were collected and subjected to TUNEL. Results showed that LNCaP cells infected with Ad/ARR 2 PB. Bax.GFP had 47% cells positive for TUNEL at 24 h after infection and 99% of cells positive at 48 h after infection. (Table 1 ). In contrast, although LNCaP/Bcl-2 cells showed similar numbers of dead cells in cytotoxicity assays following infection with Ad/ARR 2 PB.Bax.GFP, apoptosis was detected in 58% of cells staining TUNEL positive 48 h after infection. This suggests that Bcl-2, while not providing a total protective role, may still be altering the normal pathway to apoptosis and resulting in some of the cells perhaps undergoing necrotic cell death.
Systemic administration of Ad/ARR 2 PB.Bax.GFP in nude mice
To examine the activity of the ARR 2 PB promoter in vivo, intravenous injections of virus were performed. Nude mice were injected i.v. via the lateral tail vein with 5 × 10 8 p.f.u. Ad/ARR 2 PB.Bax.GFP, Ad/CMV.GFP, or PBS alone. Forty-eight hours after injection mice were killed and liver, lung, kidney, and spleen sections were harvested for histological examination. Tissue specimens were examined for signs of toxicity and found to be free of evidence of injury, specifically absence of cytoplasmic vacuolation, absence of nuclear pyknosis, absence of necrotic cells, and absense of neutrophil/lymphocyte inflammatory infiltrate in liver, lung, spleen, and kidney sections of all mice treated ( Figure 7 ).
Discussion
Tissue-specific expression of Bax through adenoviral transfer of Ad/ARR 2 PB.Bax.GFP, with restricting expression to cells able to activate the ARR 2 PB modified probasin promoter was achieved with the use of a second-generation adenoviral vector. Furthermore, we demonstrated that overexpression of Bax in LNCaP prostate cancer cells results in apoptosis as evidenced by caspase activation, as well as DNA fragmentation. The ARR 2 PB promoter requires androgen to induce activation, and this was also observed because cytotoxicity was limited to cells with an androgen receptor capable of binding androgen and functioning at the androgen response elements in the promoter. Expression of Bax in A549 lung cancer cells, Hela cervical cancer cells, and SKHep-1 liver cancer cells, was not observed. Endogenous levels of Bax and Bcl-2 were unaffected by viralexpressed Bax.
Aberrations in the apoptotic pathway have been implicated in the progression of malignancy. 11 It has been determined that both chemotherapy and radiation cause death of tumor cells through the induction of apoptosis. Furthermore, there is evidence that dysregulation of apoptosis induction occurs in malignant cells resistant to
Figure 5 Prostate-specific Bax expression induces cell death in LNCaP cells. Cell viability analysis after infection at increasing MOI with Ad/ARR 2 PB.Bax.GFP and with Ad/CMV.GFP. Cells were collected 48 h after infection, stained with 7AAD cell viability dye and analyzed by flow cytometry. With increasing MOI, cell viability decreases only in LNCaP cells and LNCaP/Bcl-2 cells. Data points are average values and standard deviation from three independent experiments. Cytotoxicity of non-prostate cancer cell lines infected with Ad/ARR 2 PB.Bax.GFP (closed circles) and Ad/CMV.GFP (closed triangles). (a) A549 human lung adenocarcinoma cell line. (b) Hela human cervical epithelial cancer cell line. (c) SK-Hep-1 human liver cancer cell line. Cytotoxicity of prostate cancer cell lines infected with Ad/ARR 2 PB.Bax.GFP (closed circles) and Ad/CMV.GFP (closed triangles). (d) CWR22RV1 human prostate cancer cell line (AR−). (e) LNCaP human prostate cancer cell line (AR+). (f) LNCaP/Bcl-2 human prostate cancer cell line (AR+).
therapy. A number of studies have been published that use cytotoxic genes to induce apoptosis in malignancies; for example, TRAIL, 25 apoptin, 26 Bcl-X S , 27 Caspase 3, 28 E2F-1, 29 FHIT, 30 and p16. 31 Among the proteins known to induce cell death, we focused on Bax for the following reasons: (1) it is a potent activator of the caspase cascade; (2) once Bax expression causes cytochrome c to be released from the mitochondria, cell death is imminent by a well described pathway; 32 and (3) Bcl-2 is known to be expressed at high levels in advanced prostate cancer which can prevent more upstream molecules from inducing apoptosis. 10, 32, 33 Overexpression of Bax causes cell death by one of two methods: apoptosis or necrosis depending on caspase involvement. 33, 34 This has been shown by addition of purified Bax protein to isolated mitochondria, which results in release of cytochrome c. 35 The anti-apoptotic proteins Bcl-2 and Bcl-X L prevent cytochrome c release. 36 Bax
Gene Therapy mediates necrotic cell death in a caspase-independent manner by release of cytochrome c involving disruption of the mitochondrial membrane potential, increased production of reactive oxygen species, and ATP depletion through loss of oxidative phosphorylation. 33 In a study using a Bax adenovirus in glioma cells (A-172), Shinoura et al 37 found that high expression levels of the anti-apoptotic Bcl-X L affected the mode of Bax-mediated cell death. They found that 80% of cell death seen was due to necrosis whereas only 5% was apoptosis. This points to the ratio of pro-apoptotic proteins to anti-apoptotic proteins in a cell as the determining factor for cell death.
High levels of Bcl-2 are found in advanced prostate cancer and have been associated with resistance to treatment and poor prognosis. 10 Therefore, Bcl-2 overexpression in LNCaP/Bcl-2 cells might have reduced the apoptotic capacity of these cells by other mechanisms. Bcl-2 and Bcl-X L have also been suggested to function by sequestering Apaf-1 (apoptosis activating factor 1) and procaspase 9 and thus preventing caspase cascade activation.
GFP or Ad/CMV.GFP or mock-infected at MOI 250, and 10 nm DHT was added. At indicated time-points after infection, cells were collected, and stained with a monoclonal antibody to the active form of caspase 3, and analyzed by flow cytometry. Mockinfected cells do not show caspase 3 activation at 48 h (a). Only background levels of caspase activation are seen in cells infected with Ad/CMV.GFP at 48 h after infection (b). No caspase 3 activation is seen in LNCaP cells infected with Ad/ARR 2 PB.Bax.GFP at 12, 18, and 24 h after infection (c, d, e). However, beginning with 36 h after infection caspase 3 activation is becoming evident (f), and at 48 h after infection caspase 3 activation is clearly seen (g).
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This leads cells towards Bax-induced necrosis resulting from the uncoupling of oxidative phosphorylation. 33 The key goals of this study were to deliver Bax expressing adenovirus and to examine expression of Bax gene and its consequence in prostate cancer cells. Attempts to construct a first-generation CMV.Bax adenovirus were unsuccessful due to the toxicity of the Bax gene in 293 packaging cells. Establishment of a 293 packaging cell line overexpressing Bcl-2 did not protect against virusmediated Bax expression. Therefore, use of a tissue-specific promoter became necessary. Previous studies revealed high-level prostate-specific activity of the ARR 2 PB modified probasin promoter in LNCaP cells expressing a secreted alkaline phosphatase reporter gene as compared with a short-form ⌬PSA promoter. 20 These data led us to construct a second-generation adenovirus with insertion of the prostate-specific ARR 2 PB promoter and Bax in an insertion site near the right ITR with the goal of shielding prostate specificity of the promoter from E1 enhancer interference. 20 This construct prevented promiscuous activation of the promoter in non-prostate cells and in non-prostate organs in nude mice. Additional studies in transgenic mice examined ARR 2 PB-mediated expression of bacterial chloramphenicol acetyltransferase (CAT) where expression was determined to be localized exclusively to the prostate. 23 The ARR 2 PB promoter is activated in cells that possess an androgen receptor (AR). LNCaP cells have a functional AR, whereas PC 3, Du145, CWR22RV1, and PPC-1 prostate cancer cells have a nonfunctional or no AR and are unable to activate the ARR 2 PB promoter. This suggests a problem might exist for treating androgen-independent prostate cancer gene therapy, however, data suggest that prostatic intraepithelial neoplasia through androgen-independent metastatic disease, largely remain AR positive and still produce PSA. 2 One proposed mechanism of androgen-independent growth of prostate tumors is that mutations in the AR render it susceptible to trans-activation by testicular androgens as well as adrenal androgens and progesterone for stimulation of growth. 38 This explanation points to androgen-independent tumor cells retaining androgen inducibility. Although androgen treatment in addition to gene therapy would be a disadvantage due to potential stimulation of prostate tumor growth, therapy involving cycling of anti-androgens and androgens has been tried. 39 Thus, Bax gene therapy may represent a novel strategy for targeting prostate cancer in androgen-competent patients.
We believe the potential of Ad/ARR 2 PB.Bax.GFP in suppressing tumorigenicity of prostate cancer should be further examined. We are currently testing the viral construct in nude mice LNCaP xenografts. Further studies of the prostate-specific promoter ARR 2 PB activity in androgen-independent prostate cancer are warranted. In conclusion, we report a promising approach for prostatespecific cancer gene therapy.
Materials and methods
Cell lines
The human LNCaP prostate epithelial cancer cell line, the human A549 lung adenocarcinoma cell line, the human SK-Hep-1 liver cancer cell line, and the human HeLa cervical epithelial cancer cell line were obtained from American Type Culture Collection (Rockville, MD, USA). The LNCaP/Bcl-2 cell line was kindly provided by Dr Ralph Buttyan (Columbia University, New York, NY, USA). The CWR22RV1 prostate cancer cell line was kindly provided by Dr JW Jacobberger (Case Western Reserve, Cleveland, OH, USA). LNCaP, CWR22RV1, and LNCaP/Bcl-2 cells were cultured in RPMI 1640 from Irvine Scientific (Santa Ana, CA, USA) supplemented with 10% fetal bovine serum from HyClone (Logan, UT, USA). The A549, SKHep-1, and HeLa cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum 
Establishment of 293/Bcl-2 cell line
The 293 human embryo kidney cell line was transfected with a plasmid containing the Bcl-2 gene driven by the cytomegalovirus (CMV) promoter and included a neomycin-resistance gene driven by the Rous sarcoma virus (RSV) promoter. The cells were cultured in IMEM with 10% fetal bovine serum with the addition of 400 g/ml Geneticin (G418) 4 days after transfection. Clones were selected for neomycin resistance and expanded. Expression of Bcl-2 was confirmed by Western blot.
Construction of plasmids and recombinant adenovirus vector
Human HA-Bax cDNA in pSFFV.Neo plasmid was generously provided by Dr Stanley Korsmeyer (Harvard Medical School, Boston, MA, USA). HA-Bax was released from pSFFV.Neo with EcoRI digestion, and cloned into the EcoRI site of pBluescript II-KS (Stratagene, La Jolla, CA, USA). HA-Bax was then released from pBluescript II-KS by digestion with XhoI and SacII and cloned into XhoI and SacII sites of pIRES2-EGFP plasmid (Clontech, Palo Alto, CA, USA). HA-Bax-Ires-GFP was released with EcoRV and XbaI and cloned into the NruI and XbaI sites of adenovirus shuttle vector pRAd.6m(ARR 2 PB.SEAP) R , replacing the SEAP reporter with the Bax-Ires-GFP construct. Construction of the pRAd.6m(ARR 2 PB.SEAP) R was described previously. 20 The pRAd.6m.ARR 2 PB.BaxIres-GFP shuttle vector was then ligated with the pLAd plasmid containing the rest of the adenoviral genome as Gene Therapy described previously. 18 This full-length adenovirus construct was transfected into 293/Bcl-2 cells to generate an Ad5 backbone with E1, E3 and E4 deletions containing ARR 2 PB.Bax.GFP in the insertion site near the right ITR. The ARR 2 PB promoter was generously provided by Dr Robert Matusik (Vanderbilt University, Nashville, TN, USA). The rAd/CMV.GFP control virus was constructed as described previously. 18 Propagation of viral vectors 293/Bcl-2 cells were transfected with the ligation mixture containing the pRAd and pLAd vector DNA. Virus was harvested at maximal cytopathic effect, plaque purified twice, twice purified by cesium chloride-gradient centrifugation and dialyzed twice. Virus was titered on 293/Bcl-2 cells by plaque-forming units per ml as well as particles per ml, in triplicate. Virus was confirmed free of replication-competent adenovirus by PCR as well as infection of the A549 lung adenocarcinoma cell line.
Visualization of morphological changes
LNCaP cells were seeded in 60-mm dishes 24 h before infection. The cells were then infected with ARR 2 PB.Bax.GFP/Ad, CMV.GFP/Ad, or mock-infected at a MOI of 250, and 10 nm dihydrotestosterone (DHT) was added. At 48 h after infection, fluorescent photographs were taken using a Pixera camera.
Western blot analysis
Western blot of Bcl-2 expression in 293 clones: Stably transfected 293 cell clones were lifted and lysed in a RIPA buffer containing a 50 mm NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mm Tris (pH 8). Total protein from cell lysates (30 g per lane) was resolved on a 12% Tris-Glycine gel, followed by transfer on to a 0.2-m polyvinylidene difluoride (PVDF) membrane. The membrane was then blocked for 1 h in Tris-buffered saline (TBS) with 5% nonfat milk. The blot was washed and subsequently probed with an anti-Bcl-2 monoclonal antibody at a dilution of 1:100 (Santa Cruz, Santa Cruz, CA, USA) at room temperature for 1 h. After washing with TBS-Tween, a secondary anti-mouse antibody conjugated to horseradish peroxidase (Santa Cruz) at a dilution of 1:50 000 was added for a 1 h incubation at room temperature. The blot was washed and developed using the Super Signal chemiluminescence kit (Pierce, Rockford, IL, USA) according to the manufacturer's protocol and exposed to radiographic film.
Time-course Western blot analysis of HA-Bax expression:
LNCaP cells were seeded in 60-mm dishes 24 h before infection. The cells were then infected with Ad/ARR 2 PB.Bax.GFP, Ad/CMV.GFP, or mock-infected at a MOI of 10. At time-points 6, 12, 24 and 48 h after infection, cells were lifted and lysed in a RIPA buffer containing a 50 mm NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mm Tris (pH 8). Total protein from cell lysates (30 g per lane) was resolved on a 4-20% Tris-Glycine gel, followed by transfer on to a 0.2-m polyvinylidene difluoride (PVDF) membrane. A Multi-Tag Marker (Santa Cruz) containing hemaglutinin protein was used as a positive control for the anti-HA antibody. The membrane was then blocked for 1 h in Tris-buffered saline (TBS) with 5% non-fat milk. The blot was washed and subsequently probed with an anti-HA monoclonal antibody (Santa Cruz) at a dilution of 1:2000, or an anti-actin polyclonal antibody (Sigma) at a dilution of 1:2000 at room temperature for 1 h. After washing with TBS-Tween, a secondary antibody conjugated to horseradish peroxidase (Santa Cruz) at a dilution of 1:50 000 was added for a 1-h incubation at room temperature. The blot was washed and developed using the Super Signal chemiluminescence kit (Pierce) according to the manufacturer's protocol and exposed to radiographic film.
Western blot analysis of Bax and Bcl-2 expression:
Cells were lysed in a RIPA buffer containing a 50 mm NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mm Tris (pH 8). Total protein from cell lysates (30 g per lane) were resolved on a 4-20% Tris-Glycine gel, followed by transfer on to a 0.2-m polyvinylidene difluoride (PVDF) membrane. The membranes were then blocked for 1 h in Tris-buffered saline (TBS) with 5% non-fat milk. The blots were washed and subsequently probed with an anti-Bax monoclonal antibody at a dilution of 1:500 (Santa Cruz), an anti-Bcl-2 monoclonal antibody at a dilution of 1:100 (Santa Cruz), or an anti-actin monoclonal antibody (Sigma) at a dilution of 1:2000 at room temperature for 1 h. After washing with TBS-Tween, a secondary antibody conjugated to horseradish peroxidase (Santa Cruz) at a dilution of 1:50 000 was added for a 1-h incubation at room temperature. The blots were washed and developed using the Super Signal chemiluminescence kit (Pierce) according to the manufacturer's protocol and exposed to radiographic film.
Cell viability assays
Cells were plated in 60-mm dishes 24 h before virus infection. The cells were then infected with Ad/ARR 2 PB.Bax.GFP or Ad/CMV.GFP or mock-infected at a range of MOIs of 0.5-500, and 10 nm DHT was added. At 48 h after infection, cells were lifted, 20 l of Via-Probe (7AAD; PharMingen, San Diego, CA, USA) was added, and cells were then analyzed by flow cytometry performed at the Flow Cytometry Core Laboratory using a Becton Dickinson FACScaliber (San Jose, CA, USA).
Time-course analysis of caspase 3 activation
LNCaP cells were seeded in 24-well plates 24 h before virus infection. At time-points 12, 18, 24, 36 and 48 h before FACS analysis, cells were infected with Ad/ARR 2 PB.Bax.GFP or Ad/CMV.GFP, or mockinfected at an MOI of 250, and 10 nm DHT was added. At 0-h time-point, cells were lifted, fixed, and permeabilized with Cytofix/Cytoperm (PharMingen) according to the manufacturer's protocol. Cells were then stained with an anti-active caspase 3 antibody (PharMingen) conjugated to phycoerythrin (PE) and analyzed by flow cytometry.
Detection of apoptosis by TUNEL method
LNCaP cells were seeded in 60-mm dishes 24 h before virus infection. At time-points 24 and 48 h before FACS analysis, cells were infected with Ad/ARR 2 PB.Bax.GFP or Ad/CMV.GFP, or mock-infected at a MOI of 250, and 10 nm DHT was added. At 0-h time-point, cells were lifted, fixed, and permeabilized with Cytofix/Cytoperm (PharMingen) according to the manufacturer's protocol. Cells were then stained with an anti-BrdU antibody (PharMingen) conjugated to phycoerythrin (PE) and analyzed by flow cytometry to determine apoptotic index.
In vivo administration of adenovirus
To assess systemic administration of virus, 5 × 10 8 p.f.u. of Ad/ARR 2 PB.Bax.GFP (n = 4), Ad/CMV.GFP (n = 3), or PBS alone (n = 3) was injected i.v. via the lateral tail vein of nude mice in a total volume of 100 l. Forty-eight hours after injection mice were killed and liver, lung, spleen, and kidney were harvested for histological examination. Formalin-fixed, paraffin-embedded tissue sections were deparaffinized, rehydrated, and H&E stained following current histological methods, and examined for signs of toxicity.
